News >

MFS Strong Surrogate Endpoint in Localized Prostate Cancer

Jason Harris
Published: Tuesday, Sep 19, 2017

Christopher J. Sweeney, MBBS
Christopher J. Sweeney, MBBS
After a median of 10 years’ follow-up, investigators with the ICECaP Working Group have concluded that there is a strong correlation between metastasis-free survival (MFS) and overall survival (OS) in patients with localized prostate cancer.

“Clearly, study durations would be shorter if the same treatment effects were assumed for MFS,” researchers wrote. “WLR analysis predicts that for OS HRs that range from 0.71 to 0.75, and corresponding MFS HRs would range from 0.65 to 0.7, so the benefit of using MFS instead of OS could be even greater.”
Xie W, Regan MM, Buyse M, et al. Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer [published online August 10, 2017]. J Clin Oncol. doi:10.1200/JCO.2017.73.9987.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication
x